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The tendency of nanoparticles to accumulate in the liver and spleen due to reticuloendothelial 
system uptake has recently become a significant issue in nanomedicine. To date, there is a lack 
of studies to determine whether gold nanoparticles compromise liver functions or viability of the 
hepatocytes. The objective of this study is to investigate the cytotoxic effect, urea and albumin 
liver functions of primary rat hepatocytes culture upon the internalization of gold nanoparticles. 
Varying concentrations of gold nanoparticles were administered to hepatocytes cultures and 
alamarBlue cell viability assay were then performed. The results revealed that the Inhibitory 
Concentration 50 to be approximately 200 nM and 700 nM for 0.5% Human Serum-coated gold 
nanoparticles and aggregated gold nanoparticles respectively. This finding demonstrated higher 
uptake and increased toxicity for the 200 nM cultures with smaller-sized nanoparticles. Urea and 
albumin secretion by the hepatocytes exhibited a dose-dependent response for both types of gold 
nanoparticles. Urea production increased with concentration for the aggregated nanoparticles 
while the opposite was observed for albumin. For the 0.5% Human Serum coated gold 
nanoparticles, urea data showed no visible changes with concentration while albumin had an 
inverse relationship similar to what was observed for aggregated particles. Both urea and 
albumin levels were measured from cell supernatant. These results shed light into the possible 
hepatic effects of gold nanoparticles internalization in the liver and compared to other published 
findings that concluded toxicity and non-toxicity of gold nanoparticles both in vitro and in vivo, 
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Chapter One: Introduction 
1.1.1 The Liver 
1.1 Background 
The liver is the largest organ in the human body and is vital for maintaining normal physiological 
homeostasis. Exiting circulation from the small and majority of the large intestine, spleen and 
pancreas are received by the liver via the portal vein.[1] The ideal location of the liver when it 
comes to reprocessing of food supply through portal vein, combined with the unique gene- and 
protein-expression patterns of hepatocytes enable it to function as a biochemical defense against 
toxic chemicals entering through food and as a re-processer of absorbed food ingredients.[1] 
Entering nutrients are transformed into secreted proteins such as albumin, most coagulation 
factors, plasma carrier proteins etc. and lipids transported as lipoproteins into other tissues and 
carbohydrates are stored as glycogen in the liver. Glycogen serves as glucose reserve in the body 
for maintaining blood glucose levels. Bile synthesized in the liver serves to assist in fat and 
lipophilic nutrients absorption. Optimal functioning of the brain also requires the liver which is a 
major regulator of plasma glucose and ammonia levels; loss of liver function will lead to chronic 
"hepatic encephalopathy" and eventual coma.[1]   
Five types of specialized cells classified into parenchymal and non-parenchymal cells are found 
in the liver. Hepatocytes are the parenchyma cells of the liver. They occupy 80% of the liver 
volume.[2] Metabolically active hepatocytes perform the metabolic functions and secretory tasks 
detailed above. Other cells are endothelial, Kupffer, stellate and epithelial cells. The endothelial 
cells allow ready exchange of materials between the perisinusoidal space and the sinusoid while 
 2 
 
Kupffer cells are macrophages of the liver and line the hepatic sinusoids that form part of the 
reticuloendothelial system (RES). As the defense system of the liver; the Kupffer cells remove 
bacteria, virus particles, fibrin-fibrinogen complexes, damaged erythrocytes and immune 
complexes from the circulation system via endocytosis. Hepatic stellate cells are responsible for 
scar tissue formation in response to liver damage. Bile duct epithelial cells transport bile and 
maintain pH.  
The liver has the remarkable ability to regenerate[3-6] as evidenced in all vertebrate organisms 
from humans to fish following loss of liver mass.[1] When livers of small animals are 
transplanted to larger animals of the same species, liver regeneration was also observed.[1] 
During the entire regenerative process, the liver continues to function in providing full support 
for body homeostasis. In a healthy liver, up to 75% of the liver can be removed and the 
remaining part of the liver will grow to its original size in six months.[7] However, when 
cirrhosis sets in, regeneration capacity is affected and liver resection for treatment of condition 
such as hepatocellular carcinoma becomes unsuitable. At present, elevated occurrences of 
cirrhosis are due to alcohol abuse, autoimmune disease of the liver, Hepatitis B and C virus 
infection and chronic inflammation of the liver.[8]  
 
1.1.2 Gold Nanoparticles - History to Present 
The possibility of using gold nanoparticles (GNP) as a future treatment alternative for some of 
the currently incurable diseases might not have occurred to people of the past who had mainly 
used them for aesthetics purposes[9] such as ceramics and glass staining. The nanoparticle-
stained glass which is famously known as the Lycurgus Cup, appears in both colours - jade green 
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and blood red - depending on whether light is shown from the front of lit from the back of the 
cup. [10, 11] Until the breakthrough in 1965 by Brill revealing presence of minute amounts of 
metallic gold and silver particles, scientists were perplexed for decades as to what had caused the 
colour-changing phenomenon.[11] Further analysis by Barber and Freestone in the 1980 
confirmed the findings of 50 to 100 nm particles through electron microscopy.[10, 11] 
In the past, people might have unknowingly created and used "GNP" without naming them as 
such since the term was only introduced much later after more was known about the particles. 
Evidence of usage in the 1920s have seen gold compounds used in therapy, initially for 
tuberculosis and later in arthritis treatment.[12] Even more surprising was the long history dating 
back to the 16th century when Swiss medical doctor and chemist Paracelsus[13] administered 
GNP to patients suffering from certain medical ailments. Present usage of gold have narrowed 
into "nanogold" to take advantage of the numerous benefits that could be derived from both gold 
and nanotechnology. 
 
1.2.1 Taking Advantage of Nanotechnology 
1.2 Motivation 
In general, nanoparticles are smaller than one hundred nanometers in size[14, 15] and their sizes 
can be compared to that of large biological molecules such as enzymes, receptors and 
antibodies[16]. Given an eukaryotic cell averages 10 to 20 µm in diameter[17], nanoparticles are 
approximately hundred to thousand times smaller than a typical eukaryotic cell. This allows for 
intimate interaction with biomolecules both on the surface of and inside of cells in a way that 
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larger molecules are incapable of doing so. Hence, nanotechnology offers great potential for 
early detection, accurate diagnosis and personalized treatment of diseases.[18]   
 
1.2.2 Insufficient Research into Biosafety of Gold 
Judging from the wide spectrum of research into GNP, one would expect to see more research 
findings translate into alternative treatment for aggressively debilitating diseases such as cancer. 
Unfortunately, the potential hazards of nanogold particles are considered of the major hurdles 
currently faced by nanoparticles research. Hesitancy on the part of regulatory authority to 
approve nanoparticles research have slowed down the bench to bedside progress. Being 
relatively new but becoming more prevalent in daily usage, there is a need to ensure that 
nanotechnology usage will not endanger both humans and the environment. One of the main 
limitations in the risk assessment of nanoparticles is the lack of toxicological data[19] and the 
lack of scientific data on long-term exposure.  
Ongoing research in gold nanoparticles for debilitating liver diseases has seen some progress 
with a research by Chen et al.[20] concluding that nanogold flakes have the potential to reduce 
alcoholic-induced injury in rats. Excess alcohol impacts heavily on the liver, bringing about three 
conditions - fatty liver, hepatitis and cirrhosis - which lead to higher incidences of liver cancer. 
The immense complexity and intricacies of the liver in regulating intermediary metabolism, 
detoxifying harmful substances, manufacturing of critical proteins and its role in excretory 
functions make the liver essential for survival since no other organs can compensate for the 
multiplicity of functions made possible by hepatocytes of the liver. Research at present have 
shown uptake of GNP by the liver[21-25], but few have investigated thoroughly the effect GNP 
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exert to the hepatocytes which provided the motivation for the author to thoroughly investigate 
their effect on uptake, hepatotoxicity and liver functions. 
 
When GNP are administered, three possible scenarios could occur: 1) GNP adhesion to cell 
surface without facing endocytosis, 2) GNP internalization by hepatocytes and clogging of 
hepatic sinusoids, and 3) GNP internalization by the hepatocytes and direct effect exerted on the 
hepatocytes. Abnormal liver functioning such as necrosis of hepatocytes and elevation of alanine 
transaminase (ALT) and aspartate transaminase (AST) levels could occur whether the GNP are 
endocytosed or adhered onto cell surface. The development of the author's hypothesis is based on 
evidence of GNP internalization by hepatocytes observed under the transmission electron 
microscope (TEM) as well as the author's interest in studying the direct effect on the hepatocytes 
following internalization. Therefore, the hypothesis was that GNP internalization directly affect 




The main objective of this thesis is to investigate the effects of GNP internalization in primary 
rat hepatocytes, specifically on cellular uptake, hepatotoxicity and liver functions. This study 
will also further explore how aggregated GNP and non-aggregated GNP (surface-coated with 




The significance of this research is to establish better toxicological understanding on how GNP 
affect the liver which could be beneficial to the biomedical community.  
1.5 Significance 
 
The scope of this work is outlined as follows: 
1.6 Scope 
 Synthesize and characterization of GNP 
 Isolation of hepatocytes from adult male Wistar rats. 
 Static culture of primary rat hepatocytes to determine (1) hepatotoxicity through alamarBlue 
Cell Viability Assay, (2) uptake of GNP imaged through confocal and (3) albumin and urea 
liver functions. 
 Investigate adsorption of human serum to GNP in an attempt to prevent aggregation when 
exposed to physiological media.  
 Compare hepatotoxicity, uptake and liver functions between human serum-coated GNP and 
aggregated GNP.  
 
This thesis is divided into five chapters. Chapter One gives a brief overview of the project which 
includes the background, hypothesis and motivation. The background section briefly explains the 
liver and roles of hepatocytes and some aspects of history and usage of GNP from past to present. 
1.7 Organization of Thesis 
 7 
 
In Chapter Two, the literature review will discuss in more details GNP and their usage in 
biomedical applications and research on effects of GNP both in vitro and in vivo. Experimental 
details are described in Chapter Three and in Chapter Four, experimental results will be analyzed 




Chapter Two: Literature Review 
2.1.1 Introduction 
2.1 Nanoparticles 
In recent years, nanoparticles are increasingly being exploited for their uses in engineering and 
sciences. The potential that nanoparticles are able to offer to these fields remains to be 
discovered and is a huge focus of interest at the moment by scientists and researchers. At present, 
nanoparticles can be synthesized and tailored into various shapes and sizes[26] and 
functionalized with antibodies[27, 28], ligands[29], and drug molecules[30]; which allow a vast 
number of applications in drug delivery[31-33], diagnostic[34-37], cancer therapy[16, 38-42] 
and imaging[18, 43-45]. Figure 2.1 illustrates nanoparticles of various shapes and sizes. 
 
Figure 2.1: Silver nanoparticles - (a) Spheres[46], (b) Pyramids[47], (c) Cubes[48], (d) Rods[47] 
 
The definition given by the Scientific Committee on Consumer Products defines a nanoparticle 
as having at least one dimension or internal structure that is in nanoscale, and a nanoscale ranges 
between 1 to 100 nm.[49] Because of this high surface area-to-volume ratio, nanoparticles are 




The history of GNP dates back to as early as in the early centuries BC. Documented data existed 
on colloidal gold usage by the Chinese, Arabian and Indian scientists for medicinal purposes[50] 
such as rheumatoid arthritis treatment and liver cancer[51, 52]. In spite of the usage, GNP did 
not gain popularity for science and medicine requirements until the discovery by Michael 
Faraday in 1857.[53] Later findings in the 1950s paved the way for immunodiagnostics and 
histopathology when GNP showed no alteration in activities with proteins adsorped onto the 
surfaces.[54] GNP are also explored for uses in DNA diagnostics and biosensors.[55] 
GNP that are spherically shaped have traditionally been used; but improvement and development 
of modern chemical methods in recent years have seen an unprecedented increase in non-
spherical nanoparticles such as nanorods, nanostars and nanocages etc. being utilized. 
Nanoparticles that are differently shaped have their own superior qualities. For example, unlike 
spherical nanoparticles, nanostars intensely absorb and scatter light near the sharp tips rather than 
by the bulk total size of nanospheres.[56] This has highlighted how differently shaped 
nanoparticles can contribute to a plethora of diverse applications; in the case of gold nanostars, 
they are suitable for combined photothermolysis[57], optical coherence tomography[58], and 
bioimaging[59].  
Figure 2.2 gives an overview of the types of GNP that can be created with present technology. 




Figure 2.2: Types of GNP: (a) Nanospheres, (b) Nanorods, (c) Bipyramids, (d) Silver-coated gold nanorods, (e) 
"Nanorice"-Fe2O3 nanorods layered with gold nanoshell, (f) Gold nanoshells with silica cores, inset showed a 
hollow gold nanoshell, (g) Nanobowls with gold seed  within, (h)"Spiky nanoshells" with SiO2/Au cores, 
nanostar shown in inset, (i) Tetrahedra, octahedra, and cubooctahedra, (j) Nanocubes, (k) Silver nanocubes 
and gold-silver nanocages obtained with silver cube templates (insets), (l) Nanonecklaces. The figure was 
reproduced from [50]. 
 
Compared to bulk gold, GNP exhibit remarkable properties which include (i) 
biocompatibility[60-62], (ii) excellent optical and chemical properties[63], (iv) ease of surface 
functionalization[61] and (v) surface plasmon resonance[53, 62, 64, 65]. Surface plasmon 
resonance is the collective oscillation of electrons caused by an electromagnetic field[66]; when 
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the frequency of the incident photons coincides with the frequencies of the oscillating electrons, 
surface plasmon resonance effect is observed. Several metals including silver, gold, copper, 
aluminium, sodium and indium exhibit surface plasmon resonance. Gold - which is especially 
resistant to oxidation - is the most practical and feasible material of choice since sodium is very 
reactive to the environment, copper and aluminium have broad surface plasmon resonance 
response, indium is too costly and silver readily oxidizes. In addition, GNP have good size 
distribution properties[67] and the gold cores are inert and non-toxic[68-70].  
GNP also have their merits in imaging. Besides ease of detection at extremely low concentration 
of 10-16 M[71]; when illuminated with white light, GNP scatter light of many colours[72] within 
the visible range of the electromagnetic spectrum which allows for tracking of the individual 
particle[73]. Light absorbed and scattered is proportional to the size of the particles (refer to 




Figure 2.3: UV-Vis absorption spectra, changes in solution color reflect increase in size of the gold 
nanoparticles.[74] 
 
2.2.1 Cancer Treatment via Enhanced Permeability and Retention Effect 
2.2 Biomedical Applications of Gold Nanoparticles 
Cancer is an aggressive disease understood as the abnormal and unrestricted growth of cells. It is 
currently the third leading cause of death in developed countries after heart disease and 
stroke.[53] At present, besides the surgical removal of the tumor, chemotherapy coupled with 
radiation therapy is best employed to reduce the size of the tumor. Chemotherapeutic drugs act 
on all actively rapidly dividing cancer cells[75], cause extreme discomfort to the patient and 
harm healthy tissues. 
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It is generally well understood from experimental tumor models and human cancer research that 
tumor tissues exhibit leaky vasculature[40, 76] and poorly developed lymphatic drainage system 
which limits the drainage of molecules from tumor tissue[77]. This passive accumulation of 
molecules within the defective and leaky endothelium layer is known as enhanced permeability 
and retention effect (Figure 2.4). Nanoparticles would preferentially accumulate and reside 
within the enlarged pore sizes of tumor vasculature than in normal healthy blood vessels where 
the endothelium layer is continuous and intact. The increased circulation time of nano-sized 
drugs is another notable aspect of enhanced permeability and retention effect since the sizes of 
these drugs exceed renal excretion threshold which limits their clearance from the bloodstream 




Figure 2.4: Enhanced permeability and retention effect - the leaky vasculature of tumor tissues allow passive 
retention of molecules within.[79]  
 
2.2.2 Photothermal therapy 
Photothermal therapy makes use of photothermal agents such as natural chromophores present in 
tissue[80-82] or external dye molecules such as indocyanine green[83], naphthalocyanines[84] 
etc. When exposed to light, the electrons of the photothermal agents get excited from the ground 
state. Eventual non-radioactive decay of the excitation energy leads to overheating of the local 
environment. The heat emitted can be used for local cell or tissue destruction.[85, 86] 
Unfortunately, natural chromophores have low absorbance while dye molecules photobleach 
under laser radiation. GNP suitability as photothermal agents is attractive due to their ability to 
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enhance absorption four to five orders of magnitude higher than photoabsorbing dyes[87], 
allowing reduction of laser power, making photothermal therapy a less invasive technique. The 
ability to enhance absorption is due to the surface plasmon resonance phenomenon exhibited by 
gold nanoparticles. GNP are also unique due to reduced photobleaching.[88] 
The principle of photothermal therapy involves using near-infrared (NIR) light which falls within 
the therapeutic optical window.[88] At this wavelength region, the tissue is mainly transparent to 
the light and thus is unable to absorb the laser light around the target region, enhancing the 
effectiveness of the therapy. Photothermal therapy has shown promising experimental results in 
cancer treatment. For example, Zharov et al.[89] studied the assembly of gold nanoclusters on 
cell membrane and found that the formation of nanoclusters resulted in increased local 
absorption and a redshift compared to normal cells without nanoclusters. When NIR laser was 
used, cancer cells killing were observed. In another study on gold nanoshells exposed to NIR 
light, Hirsch and coworkers[90] also observed death of human breast carcinoma cells through 
photothermal therapy. Huang and colleagues[91] also demonstrated the effectiveness of gold 
nanorods, with longitudinal absorption band in the NIR region on account of their surface 
plasmon resonance oscillations, as excellent photothermal agents. Remarkable results were also 
obtained with gold nanocages[92-94] and gold nanospheres[87, 95, 96]. 
 
2.2.3 Photodynamic therapy 
In photodynamic therapy, when the photosensitizer is illuminated with visible and/or NIR light, 
the photosensitizer is activated and releases reactive singlet oxygen species that rapidly react 
with biological substrate, inducing apoptosis or necrosis and eventual cell death or oxidative 
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damage.[97-99] GNP are exceptional as vehicles for delivery of photosensitizer agents. Hone et 
al.[100] used phthalocyanine-stabilized GNP (phthalocyanine acts as the photosensitizer) 
together with tetraoctylammonium bromide and observed enhanced generation of singlet oxygen 
species as compared to free phthalocyanine. In another successful case, AS1411 aptamer-
functionalized GNP bound to N-methylmesoporphyrin IX performed well in cancer therapy with 
HeLa cells.[101] 
 
2.2.4 Drug and Gene Delivery  
The goal of drug and gene delivery is best achieved when the drug/gene is delivered to the tissue 
of interest with low concentrations present in other tissues of the body. In recent years, 
nanoparticles have been tested for such targeted delivery due to similar size range to that of 
proteins and other macromolecular structures of living cells. Several advantages that can be 
derived from this kind of treatment include reduced dosage, decreased side effects, controlled 
biodistribution and better patient compliance.[102] GNP are especially attractive for this 
application due to their unique characteristics highlighted elsewhere earlier in this thesis. 
 
Drug Delivery 
Direct conjugation of drug molecules onto the surface of GNP can be achieved to increase  
treatment efficacy. This was demonstrated by Tomuleasa's group [103] who evaluated that GNP 
conjugated with anti-cancer drugs (cisplatin, doxorubicin, and capecitabine plus ribavirin) 
lowered the proliferation rates of hepatocellular carcinoma-derived cancer cells compared to 
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directly delivering the drugs alone to the cancerous cells. In another study on conjugation of 
methotrexate with 13 nm colloidal gold where the carboxylic groups on the methotrexate 
molecule is bound to the GNP surface, it was discovered that the cytotoxic effect of methotrexate 
conjugated to the gold was 7 times higher than that of free methotrexate for Lewis lung 
carcinoma cells.[104] Besides conjugation with cancer drugs, GNP can also be conjugated with 
antibiotics and other drug molecules via physical adsorption and ionic or covalent bonds. In this 
example, Saha et al. directly conjugated ampicillin, streptomycin, and kanamycin to the GNP via 
physical adsorption which revealed greater degree of inhibition in bacterial growth compared to 
using the free forms of the antibiotics alone.[105] Other studies also showed better efficiency for 
treatment of intracellular infections with antibiotics conjugated onto GNP surface.[106, 107]  
 
Gene Delivery 
Gene delivery is defined as using nucleic acids to improve disease treatment and management. 
[108] Viruses as a vehicle for gene delivery is commonly employed but prominent disadvantages 
including cytotoxicity and stimulation of immune responses[108] have prompted the search for 
solutions towards non-viral delivery systems. Nanoparticles have emerged as attractive in non-
viral gene delivery[109-111] and proved to be effective in SiRNA-based gene silencing through 
gold nanoparticles covalently functionalized with thiol-modified oligonucleotides[112]. GNP 
electrostatically bound to plasmic DNA also proved successful in inhibiting transcription by T7 




2.2.5 Imaging Contrast Agents 
Current clinical X-ray contrast agents based on tri-iodobenzene impose serious limitations such 
as short imaging time, the need for catheterization in many occasions, renal toxicity, and poor 
contrast in large patients.[114] GNP are postulated to overcome these limitations as described in 
the study by Hainfeld et al. who first conceived the idea of using GNP as an X-ray contrast agent 
in vivo.[114]  
Another important criteria in the selection of imaging contrast agent is high sensitivity, a quality 
which gold nanoparticles are justified for since it can be detected at concentration as low as 10-16 
M[71] and they scatter more intensely and brightly[68-70]. The use of GNP as contrast agent in 
confocal[115], multiphoton plasmon resonance[116], optical coherence[117] and third harmonic 
microscopy[118] have also been documented. 
Recent discovery of novel and powerful irradation-based methods to fabricate dense, stable, and 
mono-dispersed colloids[119-122] have fuelled even stronger research interest in GNP imaging 
contrast agents for the detection of cancer-related angiogenesis[123] and in vivo tumor 
imaging[124].  
 
2.2.6 Protein Detection 
Understanding the dynamics of proteins allows unravelling of related biological processes that 
occur at molecular level. Present technology is limited by labelling of the proteins with 
fluorescent dyes which, unfortunately, modifies the protein under investigation. This, in turn, 
influences the biological processes that are to be observed. GNP allow for real-time detection of  
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protein-protein interaction using localised surface plasmon resonance principle without the need 
of protein labelling as demonstrated by many research groups including Maniraj et al[125].  
 
2.2.7 Biosensors  
The resonant frequency of gold lies in the visible portion of the electromagnetic spectrum[126-
128] and any slight modifications made to the environment of the nanoparticles result in distinct 
colorimetric changes of dispersion[71, 129]. This can enhance detection even at relatively low 
excitation intensity[130], allowing for increased sensitivity in detecting small quantity of 
biomolecules which has led to the recent development of nano-bio-sensors[131-133]. 
 
GNP present huge potential benefits to the biomedical community, but little is known about both 
their short term and long term effects in organisms and environment. It is also a well-known fact 
that when materials are reduced to nanoscale, its physical and chemical properties significantly 
differ[
2.3 Toxicity of GNP 
134]. Therefore, despite the fact that gold is inert and non-toxic, it is still difficult to 
expect the same inert and non-toxic qualities for GNP; hence, the necessity for toxicity testing. 
The liver is the main organ for detoxification. Foreign particles in the body i.e. GNP are 
expected to be cleared by the liver and data obtained and analyzed by at least two research 
groups have suggested the likelihood of the GNP remaining indefinitely in the liver[25, 135]. 
The involvement of the liver indicates possibility of liver injury or damage hence it is necessary 
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to study the direct effect of GNP interaction with the liver. As far as possible, this thesis will 
attempt to discuss toxicity studies related to the liver. The definition for toxicity is varied and 
subjected to interpretation; this thesis shall define toxicity as presentation of abnormal traits. 
 
2.3.1 In vitro studies 
To the best of the author's knowledge, there are only two in vitro cases investigating GNP 
toxicity with hepatic cells/lines. Human Hep-G2 cells incubated with citrate- and 11-
mercaptoundecanoic acid-coated GNP, even after 72h exposure to the particles at concentrations 
up to 200 μM, were evaluated to exhibit no cytotoxicity via 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide reduction (MTT) and lactate dehydrogenase release (LDH) assays 
by Fraga et al.[136] No alterations in mitochondrial activity or membrane integrity were detected. 
In contrast, another study by Paino et al. observed significant viability reduction in human Hep-
G2 cells exposed to low concentrations of up to 50 μM citrate- and polyamidoamine (PAMAM) 
dendrimers-coated GNP suggesting cytotoxicity.[137] The GNP in both experiments had 
approximate diameter of 20 nm except for the PAMAM-coated particles with average diameter 
of 10.9 nm. It is surprising that both cytotoxicity studies on human Hep-G2 cells utilizing 
similarly sized citrate-coated GNP arrived at strikingly different conclusions. This reiterates the 
complexity revolving GNP cytotoxicity.  
Studies which have explored toxicity from various perspectives based on size, shape, charge, 
compositions of the nanoparticles, constituent leaching and triggering of immune reactions[138] 
had arrived at dissimilar conclusions as well. Unfortunately, due to unavailability of further 
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studies using hepatic cells/lines, the remaining part of this section will elaborate on toxicity 
findings using other cell types.  
Differently sized GNP are thought to exhibit varying degree of toxicity. Simon et al. investigated 
phosphine-functionalized GNP over a range of diameters 0.8 to 15 nm in size. Comparatively, 
the 1.4 nm-sized particles were toxic while the 15 nm particles remained non-toxic even at up to 
100-fold concentrations higher.[139, 140] The toxicity is associated with necrosis of HeLa and 
mouse monocytic/macrophage cells when treated with the 1.4 nm-sized particles while the same 
was not observed with GNP of 1.2 and 1.8 nm diameter. Another study by Chan et al.[141] with 
SK-BR-3 breast cancer cells discovered 40 and 50 nm herceptin-coated particles had the largest 
impact on basic cell signaling functions.  
Shape also plays a major role in affecting biological response as recently demonstrated by 
Schaeublin et al. whose group found that gold nanorods exerted detrimental effects to human 
keratinocyte cell line in terms of viability, mitochondrial stress, gene, and protein studies, while 
gold nanospheres did not appear to have any toxic effect.[142] 
Aggregation is a phenomenon commonly observed when nanoparticles are suspended in cell 
media or in solutions with high salt content[143-146] where ions and proteins destabilize the 
attractive Van der Waals and repulsive electrostatic forces that work to keep the particles 
monodispersed/unaggregated[147]. In general, aggregated particles that are larger in size do not 
translocate across cell membranes as easily as their monodispersed counterparts, suggesting 
decreased cellular uptake which could possibly indicate lower toxicity observed for aggregated 
particles. However the 25% decrease in uptake of aggregated GNP with Hela and A549 cells as 
reported by Alexandre and Chan[148] did not reflect any unique toxicity trend correlating to 
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aggregation, suggesting the need for more work in establishing a link between toxicity and 
aggregation. 
Stabilizing the nanoparticles with surface coating of polyethylene glycol, proteins, DNA, etc. is 
possible[148] in preventing aggregation but several experiments have demonstrated eventual 
aggregation both in vitro[144] and in vivo[149]. Research on how surface properties affect 
toxicity also needs to be taken into consideration. For instance, GNP capped with cetyltrimethyl 
ammonium bromide (CTAB) were found to be toxic to cells at low concentration, but later 
studies proved that it was actually the CTAB that was toxic.[143, 150] In another example, 
Goodman et al. compared the effect of 2 nm GNP functionalized with cationic and anionic side 
chains on Cos-1 cells and erythrocytes.[151] Toxicity sevenfold higher was observed from the 
cationic particles with lethal concentration LC50 at 1mM compared to the anionic particles with 
LC50 at 7.37mM. 
From the various in vitro experiments highlighted in this section, it is reasonable to conclude that 
there are many compounding factors affecting GNP toxicity, signifying the need for further 
studies to eliminate contradictory toxicity findings. More in vitro work testing cytotoxicity on 
hepatic cells/lines also need to be studied. 
 
2.3.2 In vivo studies 
Given that in vitro studies can only provide toxicity data on a number of cell lines and it fail to 
replicate the precise cellular condition of the situation studied, in vivo toxicity studies in animals 
will be able to offer conclusive insights into biological safety of GNP.  
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Numerous studies conducted to understand biodistribution of GNP have indicated rapid 
accumulation of the nanoparticles in the liver[21-25], indicating the central role of the liver in 
elimination of GNP. Singer and coworkers discovered that 89% of the 3-7 nm colloidal GNP had 
accumulated in the liver of mice one day after administration.[23] Similarly, McEntee and 
Ficken observed significant hepatic accumulation (93.1% +/- 2.0%) of 5-50 nm GNP.[22] 
Sadauskas and collaborators[25] studied the fate of their injected 40 nm GNP in mouse. They 
also observed significant accumulation accounting to 60% in the liver of mouse after one day. 
On the contrary, De Jong et al.[152] reported less hepatic accumulation of GNP administered 
intraveneously into rats. The group reported that only 20.8% of the 50 nm particles accumulated 
in the liver after 24 hours and 30.9% were still circulating in the bloodstream. Hainfeld et al.[114] 
also claimed low retention of 1.9 nm GNP in the liver and observed that part of their injected 
particles were eliminated through the kidneys of mice. These findings not only suggest that size 
plays an unclear role in determining nanoparticles accumulation in the liver, it also signify the 
possibility of hepatotoxicity stemming from GNP accumulation. 
Although studies have identified presence of GNP in Kupffer cells of the liver[21, 153-155], 
there has been documented evidence using TEM confirming presence of gold particles inside 
endocytotic vesicles of hepatocytes[154]. Regardless of location within the hepatocytes or 
Kupffer cells, experiments have indicated the likely role of GNP in liver damage. For example, 
10 nm and 60 nm GNP coated with PolyEthylene Glycol (PEG) were discovered to cause 
significant enhancement of ALT and AST levels[156] which indicate liver injury. Interestingly, a 
separate study found decreased ALT along with increased AST with GNP administration.[157] 
Decrease in ALT does not seem to imply any damage to the liver. In another work, Cho et al. 
showed that 13 nm PEG-coated GNP induced acute inflammation and apoptosis of hepatocytes 
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in mice.[155] Abdelhalim and Jarrar[158] also studied the effect of GNP on rats. They observed 
irregular hepatocytes necrosis, cloudy swelling of hepatocytes with nuclei displaced, increased 
Kupffer cell count and Kupffer cell hyperplasia in rats treated with the particles. It was 
postulated that oxidative stress on the hepatocytes exerted by the GNP might have caused the 
necrosis observed while swelling of the hepatocytes might indicate subacute to acute liver injury. 
Many studies have shown some form of liver toxicity related to GNP as with another study 
concluding the inhibition of cell cycle processes in the liver[24], yet a study by Chen et al.[159] 
proved no liver toxicity to rats intraperitoneally injected with GNP of average diameter 20 nm. 
It is remarkable that in vitro and in vivo studies as described herein have concluded toxicity and 
non-toxicity of GNP to the liver, further reinforcing the idea that toxicity might be largely 
dependent on factors such as surface functionalities and particle diameter. Current studies are 
also limited by the absence of long term observation on GNP in vivo.  
 
CytImmune, a nanomedicine company, was the pioneer in clinical trial with gold 
nanoparticles.[
2.4 Clinical Trials and Regulatory Approval  
160] The CYT-6091 particles were 27 nm in diameter with a gold core, surface 
bound to thiolyated PEG and recombinant human tumor necrosis factor alpha (rhTNF). PEG 
serves to impart stealth property to the particle, preventing rapid clearance by the 
reticuloendothelial system (RES) while rhTNF works to disrupt tumor blood vessels to enhance 
chemotherapy effect. Numerous human clinical trials in the past have revealed human sensitivity 
to rhTNF with toxic side effects amounting to endotoxic shock and sepsis.[161-164] The Phase I 
clinical trial was successful in three aspects: avoiding detection by the RES, delivering three 
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times the maximum tolerated dose of rhTNF at  up to 600 μg m–2 with no detectable toxicity and 
achieving GNP concentrated inside tumor tissue. 
GNP that have been approved for clinical use in diagnostic applications have different 
requirements for regulatory approval since samples are analyzed ex-vivo.[165] For injectable 
GNP, gaining approval from the U.S. Food and Drug Administration proved to be difficult as 
evidenced by the few clinical trial cases[160, 166-168]. Concerns over long term effects of GNP 
due to insufficient research will also likely add on to difficulty in securing FDA approval. Hence, 
studying the effects and excretion of GNP, especially in the liver, are key steps towards a clinical 
trial. 
 
GNP have many uses across a diverse range of medical platforms ranging from diagnostic 
imaging to cancer therapy. Most of these applications require the particles to be injected into the 
body for them to perform their desired functions. However, in order to use these particles in vivo, 
it is imperative that a thorough understanding of their behavior in vivo and the long term effects 
be made known.  
2.5 Summary 
Majority of the current research on GNP have neglected health and safety concerns. Even studies 
attempting to understand effects of GNP administration have reported contradicting data 
concluding that GNP could be toxic or non-toxic to the liver in vitro and in vivo. These 
observations are not sufficiently conclusive and will not do much to assist in gaining further 
approval from regulatory authorities for clinical trials. The end result is a failed attempt in bench 
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to bedside transition. Therefore, there is a dire need to understand hepatic effect of GNP 




Chapter Three: Experimental Details 
3.1.1 Synthesis of GNP 
3.1 Synthesis and Characterization of GNP 
Colloidal GNP were synthesized with citrate reduction method[169] according to seed-mediated 
growth. Briefly, 0.259mM of hydrogen tetrachloroaurate (Sigma-Aldrich) was reduced by 34mM 
of trisodium citrate (Sigma-Aldrich) under vigorous stirring at 90oC. The whole reaction took 15 
minutes. All glasswares and magnetic stir bars were thoroughly washed and rinsed with ultrapure 
water to prevent any unwanted nucelation and aggregation of the gold colloid solution during 
synthesis. The synthesized colloid was stored at 4oC when not in use. 
 
3.1.2 UV-Vis Characterization 
UV-Vis absorption spectrum of the colloidal gold was characterized using a UV-Vis 
spectrophotometer (Tecan infinite M1000). The path length was set to 1 cm and ultrapure water 
was used as the reference sample.  
 
3.1.3 Hydrodynamic Diameter and Zeta Potential Measurement 
A Zetasizer Nano ZS90 (Malvern Instruments) was used to measure the hydrodynamic diameter 
and zeta potential of the particles through Dynamic Light Scattering (DLS) and Laser Doppler 
Micro-electrophoresis techniques respectively.   
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3.1.4 GNP Concentration Calculation 
The full absorption spectrum of the prepared colloidal gold solution taken from 400nm to 900nm 
wavelength was used to determine the concentration of the GNP as described by Haiss et al.[170] 
The two equations used in the size calculation are presented below:  
𝑑 = exp �𝐵1 AsprA450 − 𝐵2�      (1) 
𝑑 = �Aspr�5.89x10−6�
𝑐Au exp(𝐶1) �1 𝐶2�        (2) 
In equation 1, theoretically-determined values of B1 and B2 are 3.55 and 3.11 respectively while  
experimentally-determined values of B1 and B2 are 3.00 and 2.20 respectively. Aspr refers to 
maximum absorption of the GNP at surface plasmon resonance while A450 refers to absorbance 
at 450nm. The diameter d was calculated using both theoretical and experimental values of B1 
and B2. For equation 2, theoretical values of C1 and C2 are -4.70 and 0.300 respectively while 
experimental values of C1 and C2 are -4.75 and 0.314 respectively. CAu refers to the initial gold 
concentration with the assumption that all the gold chloride will be completely reduced to gold. 
Each equation gives two different diameters using theoretical and experimental values which 
gives a total of four calculated diameters. The concentration (in terms of particle density) N is 
calculated with equation 3, using the diameter d calculated from equations 1 and 2. 
𝑁 = A450x1014
𝑑2�−0.295+1.36exp�−�𝑑−96.8
78.2 �2��         (3) 
Subsequent unit conversion yields concentration in the nM form. 
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3.1.5 TEM Imaging 
TEM (JEM-1220, JEOL Ltd., Japan) was used to measure the diameter of the gold nanoparticles 
and check the consistency of the nanoparticles obtained. 
 
Human serum obtained from human male AB plasma was purchased from Sigma-Aldrich. The 
stock concentration was assumed to be 8%. Dilution to varying concentration (0.1%, 0.5%, 1%, 
2%, 4%) was achieved with ultrapure water. Briefly, the coating was performed by incubating 
the gold nanoparticles with human serum for about 24 hours at 37oC. Subsequently, the human 
serum-coated particles were purified to remove excess human serum by centrifugation. Typically, 
the solution was centrifuged at a speed of 10,000 rpm for 25 min to precipitate the gold pellet 
and the slight yellowish supernatant was carefully removed and discarded without disturbing the 
bottom. The soft pellets obtained were then combined into a single tube and stored at 4oC.  
3.2 Preparation of GNP Coated with Human Serum 
Successful human serum corona formation on the GNP was ascertained by addition of William's 






3.3.1 Collagen Coating 
3.3 Hepatocytes Culture 
200 µl of neutralized 1.5 mg/ml Type I Bovine dermal collagen (8 ml collagen, 1 ml 0.1 M 
NaOH, 1 ml 10 × PBS and 6 ml 1 × PBS) from Vitrogen, Angiotech BioMaterials Corp. (Palo 
Alto, CA) was added onto Corning® 48-well plate (Sigma-Aldrich) at room temperature. The 
collagen was removed after 20 min and the 48-well plate was placed into a 37oC incubator 
overnight for collagen gelation to occur. 
 
3.3.2 Hepatocytes Isolation and Culture 
Primary hepatocytes were harvested from 4 weeks male Wistar rats weighing 250-300 g by a 
two-step in situ collagenase perfusion method.[171] 200-300 million cells were isolated from 
each rat with viability above 90% as determined by Trypan Blue exclusion assay. For monolayer 
culture, freshly isolated rat hepatocytes (2 x 105 cells per well) in 250 µl William's E culture 
medium were seeded on each collagen-coated well with an exposed area of 0.95 cm2. The 
William's E medium was supplemented with 1 mg/ml bovine serum albumin (BSA), 0.5 mg/ml 
of insulin, 5 nM dexamethasone, 50 ng/ml linoleic acid, 100 U/ml penicillin and 100 ug/ml 






3.4.1 Cell Viability Assessment 
3.4 Cell Viability and Hepatocyte Synthetic Functions 
GNP were added to the hepatocytes culture 24 hours after seeding (cell seeding defined as -4 h). 
After 24 hours exposure to GNP at 37oC, the hepatocytes were washed twice with 1 × PBS (pH 
7.4) to remove dead cells and excess GNP adhered to the sides of the 48-well plate. To assess 
cell viability, alamarBlue® cell viability reagent (Life Technologies) was added to the culture 
and incubated for 1 hour at 37oC before direct fluorescence measurement excitation wavelength 
of 570 nm and emission of 585 nm. Fluorescence signal was measured with UV-Vis 
spectrophotometer (Tecan infinite M1000). The control wells had no nanoparticles. Figure 3.1 
shows the alamarBlue cell viability assay protocol. 
 




3.4.2 Albumin and Urea Functional Assays 
Cell culture media samples were collected daily (20, 44, 68, 92, 116, 140 h) for cell function 
analysis. The albumin production in the culture medium was measured using a Rat Albumin 
ELISA Quantitation Kit (Bethyl Laboratories Inc., Montgomery, Texas, USA). Urea production 
in the culture medium was measured using a Urea Nitrogen Kit (Stanbio Laboratory, Boerne, 
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Texas, USA). The measurements were normalized to cell culture media obtained 4 hours after 
seeding (defined as 0 h).  
 
3.5.1 Fluorescence Staining 
3.5 Confocal 
For confocal imaging, hepatocytes were cultured in Nunc® Lab-Tek® II 8-chambered 
coverglass with 0.7 cm2 exposed area per chamber. At 24 hours after seeding, GNP suspended in 
William's E culture medium were added to the hepatocyte culture. After 4 hours, the hepatocytes 
were rinsed in 1 × PBS (pH 7.4) twice to remove excess particles that might have adhered to the 
wall of the culture chamber and then fixed with 3.7% paraformaldehyde (PFA) for 15 min at 
room temperature. Excess fixative was removed by washing with 1 × PBS (pH 7.4) thrice. The 
hepatocytes were then permeabilized with 0.1% Triton X-100 for 15 min at room temperature 
and subsequently rinsed thrice with 1 × PBS (pH 7.4) before blocking with 0.2% BSA for 15 min 
at room temperature. Blocking was performed to prevent non-specific binding. The sample was 
then rinsed thrice with  1 × PBS (pH 7.4) and then incubated in Alexa Fluor® 488 phalloidin 
(Life Technologies) for 20 min at room temperature. The stained sample was then rinsed in 1 × 
PBS (pH 7.4) thrice and further stained with DAPI (4',6-Diamidino-2-Phenylindole, 
Dihydrochloride) (Life Technologies). Alexa Fluor® 488 phalloidin stains the actin filament 




Images were captured with Olympus FluoView FV1000 (Olympus, Japan) laser scanning 
confocal microscope using a 100x/1.45 oil objective, with 599 nm solid state laser diode as the 
excitation source via reflectance mode. 405 nm and 473 nm solid state laser diode were used for 
the fluorescence imaging of actin and the nuclei.  
 




1) Cellular uptake 
Aggregated GNP 0.5% HS-coated GNP 
2) Cell viability 
3) Liver functions 
Figure 3.2: Overview of experiment showing hepatocytes fed with GNP to investigate cellular uptake, 




Chapter Four: Results and Discussion 
4.1.1 Citrate-Capped GNP 
4.1 Characterization of GNP 
Characterization is done to check for the consistency of each batch of synthesized GNP. Figure 
4.1 shows the TEM, UV-Vis absorption spectrum and hydrodynamic diameter of the GNP 
dispersed in water. TEM was used to measure the particle size of the citrate-reduced GNP. 
Figure 4.1A shows the TEM micrograph of the nanoparticles taken at 100 kX magnification. As 
can be seen, TEM confirmed the uniform spherical and monodispersity of the GNP. Further 
measurement concluded the particles with average diameter of 15 nm. The UV-Vis absorption 
spectrum of the citrate-capped GNP is shown in Figure 4.1B. The absorption spectrum shows a 
sharp peak at 520 nm typically observed for GNP of that size[172] and is due to intense localized 
surface plasmon resonance which gives rise to the distinctive red wine color[173]. 
Hydrodynamic diameter measures the size of the inorganic gold core along with the thin coating 
of citrate and the solvent layer attached to the particles as they move under the influence of 
Brownian motion. Figure 4.1C shows the measured hydrodynamic diameter at 23.0 nm.   
Zeta potential measurement reflects stability of nanoparticles. In general, nanoparticles with zeta 
potentials greater than 20 mV or less than -20 mV possess sufficient electrostatic repulsion to 
remain unaggregated in solution.[174] Evaluation of the zeta potentials of the citrate-capped 










Figure 4.1: (A) TEM micrograph of citrate-capped GNP dispersed in water, inset showed the distinctive red 
wine colour of the nanoparticles. (B) UV-Vis absorption spectrum of GNP with peak wavelength at 520 nm. 





4.1.2 Aggregated GNP 
Despite the high stability in water, citrate-capped GNP aggregated in William's E cell medium. 
Visual observation reflected the instant color change from the distinctive wine red to a black 
suspension when heavily aggregated (refer to inset of Figure 4.2A). The aggregation of the GNP 
occurred immediately. Aggregation was further confirmed with TEM analysis as shown in 
Figure 4.2A which shows almost all of the particles sticking to one another. The nanoparticles 
were imaged at 200 kX magnification. Figure 4.2B and 4.2C show the UV-Vis spectrum and 
hydrodynamic diameter of the aggregated GNP respectively. The absorption spectrum clearly 
indicates sign of aggregation. A red-shift in peak wavelength approximately centered at 642 nm 
and the appearance of a broad absorption profile which are typically observed for particles of 
larger sizes reaffirmed the effect of aggregation. The broad absorption profile might be due to 
surface charge neutralization of the GNP[175] caused by addition of the cell medium. The 
aggregated particles were found to have large variations in average hydrodynamic diameter 
ranging from 1800 to 2300 nm. Figure 4.2C shows one such measurement of aggregated GNP 













Figure 4.2: (A) TEM micrograph of citrate-capped GNP dispersed in William's E medium, inset showed the 
black suspension of aggregated GNP. (B) UV-Vis absorption spectrum of aggregated GNP with peak 







4.1.3 Human Serum-Coated GNP 
Particle aggregation and sedimentation are undesirable for biomedical applications since it can 
potentially lead to toxicity issues and reduced cellular uptake. Citrate-capped GNP exhibit 
dramatically enhanced colloidal stability when human serum (HS) is adsorbed to the surface. 
Overnight incubation of the HS-coated GNP in William's E medium at 37oC did not induce 
significant aggregation. GNP adsorbed to low concentrations of HS (0.1% and 0.5%) appeared 
reddish-pink. At higher concentration of HS, the colloidal solution turns purple with deepening 
intensity as HS concentration increases, indicating onset of slight aggregation.  
Heavily aggregated GNP present as black particulates exemplified earlier in the inset of Figure 
4.2A. The absence of serious aggregation was confirmed with UV-Vis spectrophotometer 
measurements in Figure 4.3A. Figure 4.3A shows the UV-Vis spectra for citrate-capped GNP 
with different concentrations of adsorbed HS. The presence of sharp absorbance peaks suggest 
the absence of big and agglomerated particles, hence suggesting the possibility of using HS 
corona to minimize aggregation. Aggregated GNP also have broad absorption profile previously 
described and seen in Figure 4.2B. Figure 4.3A also shows a general trend with increased 
broadening of the absorption profile as concentration of HS increases, leaning towards ease of 
GNP aggregation at higher HS concentration.    
To determine the amount of HS coating required to produce stable and monodisperse GNP, 
hydrodynamic diameter, zeta potential measurements and aggregation index were taken into 
consideration. Figure 4.3B shows the hydrodynamic diameter of GNP with different 
concentrations of adsorbed HS. Particularly, GNP with 0.5% adsorbed HS have the lowest 
average diameter of 42.6 ± 2.38 nm. Hydrodynamic diameter of the HS-coated GNP also 
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increases with increasing HS concentration. This occurrence corresponds well to the colorimetric 
observation and UV-Vis absorbance broadening profile.   
Functionalizing of GNP can mask surface charge in zeta potential measurements[176], rendering 
zeta potential slightly inaccurate to determine stability. However, zeta potential data shown in 
Figure 4.3C was still able to demonstrate good stability of GNP adsorbed to 0.1% and 0.5% HS. 
Their zeta potential were -15.07 ± 1.14 mV and -15.90 ± 1.38 mV respectively. Study has 
suggested onset of nanoparticles agglomeration with zeta potential less negative than -15 
mV[177], suggesting good stability for the 0.1% and 0.5% HS-coated GNP. Figure 4.3C also 
showed GNP with other concentrations of HS (1%, 2%, 4% and 8%) adsorbed having zeta 
potentials less negative than -15 mV, suggesting some form of instability. This is in agreement 
with other data presented and described previously. 
The aggregation index provides information on the aggregation state of the colloidal gold 
solution; it is measured by taking absorbance at 60 nm after peak wavelength divided by peak 
wavelength absorbance. Agreeing to the earlier discussions on good stability of GNP with 0.1% 
and 0.5% adsorbed HS, the aggregation index (Figure 4.3D) for these two GNP are low 
compared to GNP coated with higher concentrations of HS. The aggregation index in Figure 
4.3D increased proportionally with HS concentration, confirming increasing aggregation 
intensity as with previous discussions. The GNP with 0.1% and 0.5% adsorbed HS present no 
statistically significant difference with p<0.05. 
Taken collectively the data presented in Figures 4.3A to D, 0.5% HS-coated GNP were chosen 
since they gave the lowest hydrodynamic diameter. UV-Vis, zeta potential measurement and 
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aggregation index calculation also support for their good stability against aggregation in 
William's E medium as previously discussed.  
 
        
                                  
 
Figure 4.3: (A) Absorbance spectra, (B) Hydrodynamic diameter, (C) Zeta potential and (D) Aggregation 






Building on the previous discussion of larger hydrodynamic diameter and higher aggregation 
index with increasing HS concentration (Figure 4.3B and 4.3D respectively) which suggested 
that GNP aggregated more when the concentration of HS was increased, there is one plausible 
explanation. At 0.5% HS, the serum coating was just sufficiently enough to fully coat the 
particles. As concentration increases, there is competition among the particles for another 
complete coat around themselves and in the process, some particles would be competing for the 
same serum molecule which resulted in the occurrence of slight aggregation. 
 
AlamarBlue has been relatively recently applied in nanotoxicity studies[
4.2 Cell Viability 
178] to quantitatively 
measure cell viability for assessing cytotoxicity[179]. Viable cells continuously convert blue 
resazurin present in alamarBlue reagent to red resorufin.  
For the aggregated citrate-capped GNP, concentrations of 1, 10, 100, 300, 500, 600, 700 and 
1000 nM were used. The control wells (0 nM) had no GNP. Referring to Figure 4.4A, a 
sigmoidal curve is obtained which shows decreasing cell viability with increasing concentration 
of GNP administered. The 50% cytotoxicity concentration (IC50) is 700 nM. The IC50 is the 
dosage of drug to kill 50% of the cells population. 
Figure 4.4B shows a similar sigmoidal curve obtained for 0.5% HS-coated GNP which shows a 
reduction in cell viability with higher concentration of GNP. Concentrations of 1, 10, 100, 200 
and 300 nM were administered to the hepatocytes.  Control wells (0 nM) were kept free of GNP. 
The IC50 is approximately 200 nM. 
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A side-by-side comparison of the IC50 values obtained for the aggregated and 0.5% HS-coated 
GNP shows lower IC50 for the 0.5% HS-coated GNP by 3.5 fold, suggesting higher uptake of the 
smaller, non-aggregated HS-coated GNP than the aggregated GNP. Alexandre and Warren who 
compared uptake of aggregated and non-aggregated GNP also observed 25% reduction of uptake 
of aggregates by HeLa and A549 cells[148]. The deduction of higher uptake of 0.5% HS-coated 
GNP here was not surprising since theoretical models predicted optimal diameter for receptor-
mediated endocytosis to be approximately 50 nm[180-182] which coincided with the 
hydrodynamic diameter averaging 42.6 ± 2.38 nm for the 0.5% HS-coated GNP.   
It is understood that GNP have good cell biocompatibility[60-62]. The addition of 1 nM 0.5% 
HS-coated GNP caused a sharp drop in viability largely due to two reasons: 1) usage of primary 
cells which are not as robust as cell line cultures and 2) smaller GNP sizes for 0.5% HS-coated 
compared to the much larger aggregated particles and hence 0.5% HS-coated particles exhibited 
higher uptake. However, the usage of primary cells is particularly suited to this study as it fully 
reflects the effect on hepatocytes which are parenchyma cell of the liver and perform a vast 
number of functions to sustain bodily functions. 
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Figure 4.4: Cell viability at different concentrations of (A) Aggregated GNP and (B) 0.5% HS-coated GNP 
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4.3.1 Urea Excretory Function 
4.3 Hepatocyte Synthetic Function 
The urea functional level was examined and compared against the control which has no GNP. 
With reference to Figure 4.5, hepatocytes incubated with aggregated GNP exhibited higher urea 
production than the control at 44 h for all concentrations of GNP except at 700 nM. 
Subsequently, urea levels show a downward fluctuating trend with time. At 140 h, urea 
productions for concentrations up to 600 nM were found to have stabilized with control urea 
level, suggesting possibility of hepatocytes' recovery in urea production after removal of GNP at 
44h. Only hepatocytes fed with 700 nM aggregated GNP show a consistent downward trend in 
urea level which coincides with the IC50.  




























Figure 4.5: Hepatocyte urea function at different time points for aggregated GNP concentrations of 1, 10, 100, 
300, 500, 600 and 700 nM 
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Figure 4.6 shows the hepatocyte urea function for 0.5% HS-coated GNP. Interestingly, at 44 h, 
urea production for all concentrations are found to be relatively similar to control urea 
production; unlike what was observed with aggregated GNP. Hepatocytes incubated with the 
smaller-sized GNP also yielded higher urea level than the control at concentrations up to 200 nM 
at all time points. One plausible explanation for the elevated urea levels could be due to digestion 
of proteins (not involved in blood clotting) present in HS by the hepatocytes. Similar to the trend 
observed with aggregated GNP, urea levels eventually seem to fall back to control urea 
production at 140 h, suggesting the short term effect exerted by 0.5% HS-coated GNP on the 
hepatocytes. Especially for hepatocytes fed with 300 nM 0.5% HS-coated GNP, urea level at 140 
h was lower than the control which is not surprising since the concentration has exceeded the 
IC50. 


























Figure 4.6: Hepatocyte urea function at different time points for 0.5% HS-coated GNP concentrations of 1, 10, 
100, 200 and 300 nM 
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When urea production was plotted against GNP concentration as shown in Figure 4.7, hepatocyte 
urea production at 44 h increased with aggregated GNP concentrations up to 500 nM before 
decreasing drastically. At all time points of 44, 68, 92, 116 and 140 h, a downward trend in urea 
levels was also observed starting from 500 nM, suggesting the likelihood that higher 
concentrations of aggregated GNP effecting the hepatocytes.  






























Figure 4.7: Hepatocyte urea production versus aggregated GNP concentration at time points 44, 68, 92, 116 





Referring to Figure 4.8, hepatocyte urea production at 44 and 68 h remained relatively constant 
for all concentrations of 0.5% HS-coated GNP. At 92 and 116 h, urea production showed a 
generally upward trend as concentration of GNP increases. Urea level at these two time points 
were higher than that observed at 44 and 68 h. At 140 h, hepatocytes exhibited decreased  urea 
production than at other time points, probably stemming from lower viability of the cells at this 
time point due to monolayer culture. 


























Figure 4.8: Hepatocyte urea production versus 0.5% HS-coated GNP concentration at time points 44, 68, 92, 






4.3.2 Albumin Synthesis Function 
Albumin is an essential protein synthesized by the liver; lower than normal level of albumin is 
usually characterized with severe chronic liver disease. From Figure 4.9, hepatocytes incubated 
with aggregated GNP exhibit varying albumin levels that seem to show a general trend of lower 
albumin level with increasing GNP concentration. At 24 h after incubation with GNP, 
hepatocytes given 300, 500, 600 and 700 nM of aggregated GNP exhibited much lower albumin 
secretion than the control hepatocytes. For hepatocytes with lower concentrations of aggregated 
GNP (1, 10, 100 nM), albumin level increased from 24 h time point was not significant and was 
comparable to the control (dashed line); suggesting that lower concentrations of GNP did not 
cause a drastic reduction in albumin synthesis, thus indicating normal functioning of the 
hepatocytes. At 92 h, hepatocytes previously incubated with 300 and 500 nM of aggregated GNP 
showed recovery in albumin synthesis. The normalized albumin level for these two 
concentrations increased from 4.72 ± 1.84 and 3.50 ± 0.67 at 44 h to 5.53 ± 1.42 and 5.17 ± 1.68 
at 92 h respectively; and these values were relatively similar to normalized albumin values for 
hepatocytes previously fed with 1, 10 and 100 nM of aggregated GNP. In addition, hepatocytes 
given 24 h of 1, 10 and 100 nM of aggregated GNP in general had higher albumin level than 
control at all time points and this was later observed with the 300 and 500 nM at 92 h onwards. 
Hepatocytes given 600 and 700 nM aggregated GNP exhibited lowered albumin production than 
control. This finding is not unexpected around IC50 value. At 140 h, normalized albumin level for 
all concentrations of GNP coalesce at roughly the same point even for hepatocytes given the 
highest dosage of GNP, suggesting temporary effect of the aggregated GNP on the hepatocytes. 
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Figure 4.9: Hepatocyte albumin function at different time points for aggregated GNP concentrations of 1, 10, 








Figure 4.10 illustrates the trend observed for hepatocyte albumin functions with 0.5% HS-coated 
GNP. For 0.5% HS-coated GNP, hepatocytes fed with low concentrations of GNP (1 and 10 nM) 
secrete slightly higher normalized albumin levels at all time points compared to the control 
hepatocytes secretion while those with higher concentrations of GNP as in the case of 100, 200 
and 300 nM showed lower than normal normalized albumin levels. Interestingly, similar to what 
was observed with aggregated GNP; hepatocytes given GNP concentrations near IC50 (200 and 
300 nM) showed consistently lower albumin levels than the control at all time points. In addition, 
hepatocytes given 0.5% HS-coated GNP also showed normalized albumin levels coalescing at 
140 h, suggesting the temporary effect of GNP on the hepatocytes after internalization. 



























Figure 4.10: Hepatocyte albumin function at different time points for 0.5% HS-coated GNP concentrations of 
1, 10, 100, 200 and 300 nM 
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Figures 4.11 and 4.12 show albumin synthesis for aggregated GNP and 0.5% HS-coated GNP 
plotted with respect to GNP concentration respectively. Evident from Figure 4.11, albumin levels 
show no significant changes at 44 h for aggregated GNP concentrations up to 100 nM before 
experiencing a drastic albumin synthesis decrease as aggregated GNP concentration increases. 
Similar trend is also seen at 68 h. Albumin levels at both 92 h and 116 h remain relatively 
constant at aggregated GNP concentrations up to 300 nM before decreasing as concentration 
increases. At 140 h, synthesized albumin remains constant at all concentrations. 
































Figure 4.11: Hepatocyte albumin synthesis for aggregated GNP concentration at time points 44, 68, 92, 116 




Figure 4.12 shows increased albumin synthesis at all time points from 0 to 10 nM before 
reduction is observed as 0.5% HS-coated GNP increases. Both Figures 4.11 and 4.12 show 
expected reduction in albumin synthesis with time as the collagen extracellular matrix layer in 
monolayer culture is unable to sustain consistent enhanced albumin function after a certain 
timeframe. 
 




























Figure 4.12: Hepatocyte albumin synthesis for 0.5% HS-coated GNP concentration at time points 44, 68, 92, 





Confocal microscopy combining the fluorescence of dye molecules (Alexa Fluor® 488 marking 
the boundary and DAPI for nuclei of the hepatocytes) and the scattered light of the GNP was 
used to obtain compound cellular images of the hepatocytes. There are two modes of imaging 
available in confocal microscopy: (1) fluorescence and (2) reflectance. In confocal reflectance 
used in this study, laser with wavelength 559 nm was shone on the hepatocytes cultured on glass 
chamber and the reflected light at the same wavelength was collected. The reflected light 
includes reflection from background, collagen matrix and GNP. By using the control chamber 
with no GNP as the reference, background and collagen reflection can be subtracted and the 
reflection intensity could be quantified to detect for traces of GNP internalized in the hepatocytes 
and trend to show relation of dosage with uptake which unfortunately is out of scope for this 
thesis. 
4.4 Confocal Microscopy 
As can be seen from Figure 4.13, healthy hepatocytes cultures form tight junctions into 
branching plates of cells, usually only one cellular layer thick. The bile canaliculi are indicated 
with white arrows in the compound cellular images which contain both the reflection from the 
GNP (red) and fluorescence from the hepatocytes with nuclei and cell membrane immunostained 
blue and green respectively. Images for hepatocytes incubated with different concentrations of 














Figure 4.13: 2D confocal images of hepatocytes with tight junctions (white arrows indicate bile canaliculi): (A) 






Chapter Five: Conclusions 
GNPs have a plethora of uses across different medical platforms; ranging from bioimaging, 
cancer therapy to drug and gene delivery. Despite the recent excitement revolving research 
advancement in nanomedicine, few studies have attempted to understand the effect of GNP to 
the liver. In vitro and in vivo studies conducted by research groups worldwide have discovered 
contradictory results which seem to point possible toxicity and non-toxicity of GNP. 
Compounding factors such as size, shape and functionalization groups on the particles make 
matters more complicated. Hence, this research aims to bridge the minimal understanding of the 
effects of GNP on uptake, liver functions and hepatotoxicity. Due to aggregation phenomenon 
presented by citrate-capped GNP, 0.5% HS-coated GNP was used in the later part of the study in 
an attempt to compare how uptake, liver functions and hepatotoxicity differ between these two 
types of nanoparticles.  
Monolayer hepatocytes culture were seeded and allowed to stabilize before addition of varying 
concentration of GNP for 24 h. Hepatotoxicity determined from alamarBlue assays indicated 
lower IC50 for the aggregated GNP. The aggregated GNP had approximate IC50 of 700 nM while 
IC50 for 0.5% HS-coated GNP was about 200 nM. Urea and albumin liver functions measured 
from cell supernatant exhibit a dose-dependent response and the trend seemed to show recovery 
in production of urea and synthesis of albumin after removal of GNP from the culture. Confocal 
imaging confirmed the presence of uptake of the GNP for both aggregated and monodispersed 
form. 
These findings are significantly beneficial to the biomedical community as a whole since the 
liver is the organ of the reticuloendothelial system which plays an important and essential role in 
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defending our system from foreign invaders. However, in vitro studies alone are usually not 
sufficiently conclusive due to the complexity of the human body. Thus, future directions for this 
research might consider exploring in vivo administration of the GNP to gain a better 
understanding on biodistribution which is limited by in vitro work. Furthermore, methods could 
be researched into synthesizing of GNP which offer higher yield and stability in different 
solvents.  
In addition, as outlined in the results and discussion section, the usage of primary hepatocytes in 
this study is significant in that it more accurately reflect how GNP exert a toxic/non-toxic effect 
on the liver since hepatocytes occupy 80% of liver volume and perform important metabolic and 
excretory activities to maintain bodily functions. Moreover, numerous studies attempting to 
understand possible toxicity of GNP have attempted on either hepatic cell lines or other cell 
types which are not sufficiently conclusive to provide a satisfactory explanation on GNP toxicity 
particularly to the liver. The study method employed in this thesis is novel and original since no 
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Figure B: 2D confocal images showing hepatocytes at different concentrations of 0.5% HS-coated GNP. 
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